| Title: |
SYLENTIS S.A. - RNAi biopharmaceuticals |
| Description: |
SYLENTIS, biotechnology company focused on the development of new ophthalmic drugs and novel therapies based on RNAi (gene silencig) technology. Addressed diseases in its pipeline includes dry eye, retina diseases, glaucoma or allergies. SYLENTIS is one of the pioneer companies devoted to siRNA, with one of the most advanced siRNA design technologies worldwide, researching on an extense range of Ophtalmical Therapeutic areas and indications. Most advanced experimental drugs: Bamosiran and Tivanisiran. |
| Category: |
Science > Biology > Biochemistry and Molecular Biology > Gene Expression > RNA Interference > Products and Services |
| Keywords: |
Bamosiran
Tivanisiran
Sylentis RNA company
RNAi
Interference RNA
Gene Silencing
siRNA
Ophthalmics
Ophthalmology
Dry Eye
Glaucoma Allergies
DMAE
RETINA
Retinopathies
Alnylam
Quark
Phase III
Experimental drugs.
Ocular allergies |
| Plot IP Analysis: |
The domain sylentis.com is hosted from IP address 83.175.205.46, having reverse-lookup exchange.sylentis.com and inward-pointing nameservers ns02.domaincontrol.com, and ns01.domaincontrol.com. Our records show that other domains are hosted from this IP, such as sylentis.com. The server hosting sylentis.com is located in a data center in Madrid, Madrid, Comunidad de, Spain. |